Peptide hitting both GLP-1 and apelin receptors protects neurons in a mouse Parkinson's model
- A single bifunctional peptide, ELA, fuses an exendin-4 GLP-1 agonist element with apelin to engage both receptor systems.
- In MPTP-lesioned mice, benchmarked against liraglutide, it improved movement and dampened neuroinflammation.
- It also preserved striatal synapses and restored mitochondrial fission/fusion balance, beating liraglutide on some readouts but not all.
💡 Points Based on the abstract
Beating liraglutide only on some readouts in one MPTP model is a thin basis for calling dual agonism better, since acute MPTP recovers spontaneously and barely mimics progressive alpha-synuclein pathology. Without brain exposure, a dose-response, and a mixed GLP-1 plus apelin co-dosing arm, you can't tell synergy from simply higher potency. Next: pharmacokinetics, then a chronic or alpha-syn model.